Mark L. Jacobson, Chief Operating Officer of Axsome Therapeutics ($AXSM), sold about $19.1 million worth of company shares in seven open market transactions over the last year. His most recent sale occurred on February 26, 2026. These sales rank him 699th among 11,678 insiders by total value sold, above the average of $8.6 million across roughly 6.4 transactions per insider. Jacobson made no open market purchases during this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 26, 2026 | Axsome Therapeutics, Inc. | $AXSM | Jacobson Mark L. | Chief Operating Officer | S | Common Stock | 35378 | $161.88 | 0.0000 | 50,412,640 | 100.00% | 0.07% |
| Feb. 26, 2026 | Axsome Therapeutics, Inc. | $AXSM | Jacobson Mark L. | Chief Operating Officer | M | Common Stock | 35378 | $2.85 | 35,378.0000 | 50,412,640 | 9999.99% | 0.07% |
| Feb. 26, 2026 | Axsome Therapeutics, Inc. | $AXSM | Jacobson Mark L. | Chief Operating Officer | A | Restricted Stock Units | 19663 | $0.00 | 19,663.0000 | 50,412,640 | 9999.99% | 0.04% |
| Feb. 26, 2026 | Axsome Therapeutics, Inc. | $AXSM | Jacobson Mark L. | Chief Operating Officer | M | Stock Option (Right to Buy) | 35378 | $0.00 | 0.0000 | 50,412,640 | 100.00% | 0.07% |
| Sept. 22, 2025 | Axsome Therapeutics, Inc. | $AXSM | Jacobson Mark L. | Chief Operating Officer | M | Stock Option (Right to Buy) | 10000 | $0.00 | 35,378.0000 | 48,765,403 | 22.04% | 0.02% |
| Sept. 22, 2025 | Axsome Therapeutics, Inc. | $AXSM | Jacobson Mark L. | Chief Operating Officer | S | Common Stock | 10000 | $115.96 | 0.0000 | 48,765,403 | 100.00% | 0.02% |
| Sept. 22, 2025 | Axsome Therapeutics, Inc. | $AXSM | Jacobson Mark L. | Chief Operating Officer | M | Common Stock | 10000 | $2.85 | 10,000.0000 | 48,765,403 | 9999.99% | 0.02% |
| Sept. 16, 2025 | Axsome Therapeutics, Inc. | $AXSM | Jacobson Mark L. | Chief Operating Officer | M | Stock Option (Right to Buy) | 15000 | $0.00 | 0.0000 | 48,765,403 | 100.00% | 0.03% |
| Sept. 16, 2025 | Axsome Therapeutics, Inc. | $AXSM | Jacobson Mark L. | Chief Operating Officer | M | Stock Option (Right to Buy) | 25000 | $0.00 | 0.0000 | 48,765,403 | 100.00% | 0.05% |
| Sept. 16, 2025 | Axsome Therapeutics, Inc. | $AXSM | Jacobson Mark L. | Chief Operating Officer | S | Common Stock | 40000 | $114.23 | 0.0000 | 48,765,403 | 100.00% | 0.08% |
| Sept. 16, 2025 | Axsome Therapeutics, Inc. | $AXSM | Jacobson Mark L. | Chief Operating Officer | M | Common Stock | 15000 | $4.85 | 40,000.0000 | 48,765,403 | 60.00% | 0.03% |
| Sept. 16, 2025 | Axsome Therapeutics, Inc. | $AXSM | Jacobson Mark L. | Chief Operating Officer | M | Common Stock | 25000 | $4.95 | 25,000.0000 | 48,765,403 | 9999.99% | 0.05% |
| Sept. 16, 2025 | Axsome Therapeutics, Inc. | $AXSM | Jacobson Mark L. | Chief Operating Officer | S | Common Stock | 5783 | $116.19 | 0.0000 | 48,765,403 | 100.00% | 0.01% |
| June 9, 2025 | Axsome Therapeutics, Inc. | $AXSM | Jacobson Mark L. | Chief Operating Officer | M | Common Stock | 25000 | $8.02 | 30,783.0000 | 48,765,403 | 432.30% | 0.05% |
| June 9, 2025 | Axsome Therapeutics, Inc. | $AXSM | Jacobson Mark L. | Chief Operating Officer | S | Common Stock | 25000 | $110.44 | 5,783.0000 | 48,765,403 | 81.21% | 0.05% |
| June 9, 2025 | Axsome Therapeutics, Inc. | $AXSM | Jacobson Mark L. | Chief Operating Officer | M | Stock Option (Right to Buy) | 25000 | $0.00 | 0.0000 | 48,765,403 | 100.00% | 0.05% |
| May 28, 2025 | Axsome Therapeutics, Inc. | $AXSM | Jacobson Mark L. | Chief Operating Officer | M | Stock Option (Right to Buy) | 20000 | $0.00 | 0.0000 | 48,765,403 | 100.00% | 0.04% |
| May 27, 2025 | Axsome Therapeutics, Inc. | $AXSM | Jacobson Mark L. | Chief Operating Officer | M | Common Stock | 20673 | $6.47 | 26,456.0000 | 48,765,403 | 357.48% | 0.04% |
| May 27, 2025 | Axsome Therapeutics, Inc. | $AXSM | Jacobson Mark L. | Chief Operating Officer | S | Common Stock | 20673 | $104.66 | 5,783.0000 | 48,765,403 | 78.14% | 0.04% |
| May 28, 2025 | Axsome Therapeutics, Inc. | $AXSM | Jacobson Mark L. | Chief Operating Officer | M | Common Stock | 20000 | $6.47 | 25,783.0000 | 48,765,403 | 345.84% | 0.04% |
| May 28, 2025 | Axsome Therapeutics, Inc. | $AXSM | Jacobson Mark L. | Chief Operating Officer | S | Common Stock | 20000 | $103.45 | 5,783.0000 | 48,765,403 | 77.57% | 0.04% |
| May 27, 2025 | Axsome Therapeutics, Inc. | $AXSM | Jacobson Mark L. | Chief Operating Officer | M | Stock Option (Right to Buy) | 20673 | $0.00 | 0.0000 | 48,765,403 | 100.00% | 0.04% |
| Feb. 24, 2025 | Axsome Therapeutics, Inc. | $AXSM | Jacobson Mark L. | Chief Operating Officer | A | Performance Stock Units | 10769 | $0.00 | 10,769.0000 | 48,765,403 | 9999.99% | 0.02% |
| Feb. 21, 2025 | Axsome Therapeutics, Inc. | $AXSM | Jacobson Mark L. | Chief Operating Officer | A | Restricted Stock Units | 10769 | $0.00 | 10,769.0000 | 48,765,403 | 9999.99% | 0.02% |
| Feb. 21, 2025 | Axsome Therapeutics, Inc. | $AXSM | Jacobson Mark L. | Chief Operating Officer | A | Employee Stock Option (Right to Buy) | 10875 | $0.00 | 10,875.0000 | 48,765,403 | 9999.99% | 0.02% |
| Aug. 9, 2024 | Axsome Therapeutics, Inc. | $AXSM | Jacobson Mark L. | Chief Operating Officer | S | Common Stock | 47739 | $84.26 | 5,783.0000 | 0 | 89.20% | 0.00% |
| Aug. 9, 2024 | Axsome Therapeutics, Inc. | $AXSM | Jacobson Mark L. | Chief Operating Officer | M | Common Stock | 47739 | $4.04 | 53,522.0000 | 0 | 825.51% | 0.00% |
| Aug. 9, 2024 | Axsome Therapeutics, Inc. | $AXSM | Jacobson Mark L. | Chief Operating Officer | M | Stock Option (Right to Buy) | 47739 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| May 29, 2024 | Axsome Therapeutics, Inc. | $AXSM | Jacobson Mark L. | Chief Operating Officer | M | Common Stock | 13693 | $1.30 | 13,693.0000 | 0 | 9999.99% | 0.00% |
| May 29, 2024 | Axsome Therapeutics, Inc. | $AXSM | Jacobson Mark L. | Chief Operating Officer | M | Stock Option (Right to Buy) | 13693 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| May 29, 2024 | Axsome Therapeutics, Inc. | $AXSM | Jacobson Mark L. | Chief Operating Officer | S | Common Stock | 7910 | $74.31 | 5,783.0000 | 0 | 57.77% | 0.00% |
| April 1, 2024 | Axsome Therapeutics, Inc. | $AXSM | Jacobson Mark L. | Chief Operating Officer | M | Common Stock | 24662 | $1.30 | 24,662.0000 | 0 | 9999.99% | 0.00% |
| April 1, 2024 | Axsome Therapeutics, Inc. | $AXSM | Jacobson Mark L. | Chief Operating Officer | M | Stock Option (Right to Buy) | 24662 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| April 1, 2024 | Axsome Therapeutics, Inc. | $AXSM | Jacobson Mark L. | Chief Operating Officer | S | Common Stock | 24662 | $77.24 | 0.0000 | 0 | 100.00% | 0.00% |
| Feb. 27, 2024 | Axsome Therapeutics, Inc. | $AXSM | Jacobson Mark L. | CHIEF OPERATING OFFICER | A | Employee Stock Option (Right to Buy) | 32825 | $0.00 | 32,825.0000 | 0 | 9999.99% | 0.00% |
| Feb. 27, 2024 | Axsome Therapeutics, Inc. | $AXSM | Jacobson Mark L. | CHIEF OPERATING OFFICER | A | Restricted Stock Units | 18027 | $0.00 | 18,027.0000 | 0 | 9999.99% | 0.00% |
| March 2, 2023 | Axsome Therapeutics, Inc. | $AXSM | Jacobson Mark L. | CHIEF OPERATING OFFICER | A | Employee Stock Option (Right to Buy) | 41424 | $0.00 | 41,424.0000 | 0 | 9999.99% | 0.00% |
| March 2, 2023 | Axsome Therapeutics, Inc. | $AXSM | Jacobson Mark L. | CHIEF OPERATING OFFICER | A | Restricted Stock Units | 23491 | $0.00 | 23,491.0000 | 0 | 9999.99% | 0.00% |